An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Sunosi

Chemical Namesolriamfetol
Dosage FormTablet (oral; 75 mg, 150 mg)
Drug ClassInhibitors
SystemNervous
CompanyJazz Pharmaceuticals Inc.
Approval Year2019

Indication

  • Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sunosi (solriamfetol) Prescribing Information2019Jazz Pharmaceuticals
Document TitleYearSource
Assessment report – sunosi2019EMA
Document TitleYearSource
Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.2020Sleep Medicine